GleamWall
中文EN

MTRI InMed Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30

Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—

Margins

Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x

Leverage & solvency

Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue———$820,188$1.12M$1.30M$1.26M$1.11M
Cost of revenue———$635,994$716,962$728,056$1.09M$650,813
Gross profit———$184,194$403,159$576,654$175,625$460,894
R&D expense$206,015$805,741$1.02M$630,636$575,458$577,254$425,370$895,176
SG&A expense$1.80M$2.36M$1.74M$1.62M$1.24M$1.26M$1.58M$1.72M
Pretax income-$2.00M-$4.84M-$2.79M-$2.03M-$1.83M-$1.83M-$2.07M-$2.58M
Net income-$2.33M-$5.84M-$2.97M-$2.03M-$1.73M-$1.79M-$2.12M-$2.58M
EPS (basic)-0.42—-0.73-0.51-0.44—-1.94-3.64
EPS (diluted)-0.42—-0.73-0.51-0.44—-1.94-3.64
Weighted avg. shares (diluted)5.47M—4.05M3.95M3.95M—1.10M706,546
Balance sheet
Cash & equivalents$1.09M$2.19M$5.16M$6.95M$8.68M$10.74M$4.68M$3.42M
Short-term investments$40,331$39,670$41,625$42,675$42,859$43,384$40,582$40,787
Receivables———$182,967$343,469$465,104$367,813$262,569
Inventory———$947,898$890,807$961,173$813,970$1.10M
Current assets$1.26M$2.68M$6.89M$8.79M$10.80M$12.87M$6.41M$5.47M
PP&E, net—$221,037$642,884$764,254$881,549$992,199$1.11M$1.23M
Intangibles——$1.50M$1.54M$1.58M$1.62M$1.66M$1.70M
Total assets$1.31M$3.03M$9.13M$11.19M$13.36M$15.58M$9.28M$8.50M
Current liabilities—$1.96M$2.21M$1.48M$1.55M$1.84M$1.84M$1.79M
Total liabilities$2.51M$1.96M$2.24M$1.60M$1.77M$2.15M$2.26M$2.32M
Shareholders' equity-$1.20M$1.08M$6.89M$9.59M$11.59M$13.43M$7.02M$6.18M
Shares outstanding5.49M5.34M3.31M2.80M2.60M2.00M1.21M724,152
Cash flow statement
Operating cash flow-$1.14M-$2.96M-$1.70M-$2.38M-$1.93M-$1.78M-$1.66M-$2.50M
Investing cash flow$2,417———————
Financing cash flow$40,000-$1$231,675$0-$137,178$8.17M$2.92M$338,521
Depreciation & amortization$168$48,359$51,707$53,201$53,202$52,752$51,706$53,202
Stock-based compensation$16,375$22,626$38,771$25,564$20,205$26,730$40,454$23,159

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.